Theraclone setback as BARDA says no to flu MAb
This article was originally published in Scrip
Executive Summary
Theraclone Sciences, which announced a merger with PharmAthene recently, will not get Phase II of its lead monoclonal antibody candidate for serious flu paid for by BARDA. The Biomedical Advanced Research and Development Authority has decided not to use federal funds to bankroll the proposal, which Theraclone submitted in August.